

# POST-SSRI'S SEXUAL DISORDERS (PSSD)

Y. Reisman MD, PhD, FECSM  
Sexuality Clinics  
The Netherlands



# SSRI's: Indications & Use

- Depressive disorder
- Anxiety disorder
- OCD
- Panic attacks
- PTSD
- PE
- Prevalence: up to 7% of US population
- SSRI's are the 3<sup>rd</sup> most often prescribed medication in US
- In NL: 3% of population use SSRI

# SSRI's: Sexual Side-Effects

- Decreased libido
- Erectile dysfunction/decreased lubrication
- Ejaculatory disorders (Delayed)
- Delayed/Anorgasmia
  
- Anesthesia of genitals
- PGAS

- Depression or SSRI ?
  
- SSRI side-effect

- **Prevalence up to 70%**
- **Due to activation of the 5-HT<sub>2A</sub> receptors**
- **Endure for the duration of treatment, assume to be resolved upon discontinuation**

# Desire, Arousal & Depression

- Depression - **Decreased** desire in
  - 40 % of men
  - 50% of women (variability up to 70%)
- Depression – **Increased** desire in
  - 23% of men
  - 9 % of women
- Increased risk of
  - OR-3.4 for erectile dysfunction
  - OR-2.3 for vaginal dryness
- Nocturnal penile tumescence is decreased in 40% of men with depression


# Ejaculation, Orgasm & Depression

- 15-25% increased risk of premature or delayed ejaculation
- 40 % of women report orgasmic problems
- Large variability in studies

# The Effect of Psychopharmaca on Sexual Function


- Unspecific:
  - Overweight, tiredness
- Specific effect on CNS neurotransmitters:
  - serotonin, noradrenaline, dopamin, NO, cholinergic system
- Direct hormonal effect:
  - Prolactin
- Indirect hormonal effect
  - SHBG & metabolic syndrome

# Central Effects of Neurotransmitters & Hormones on Sexual Functioning





# Peripheral Effects of Neurotransmitters & Hormones on Sexual Functioning



## More about Anti-depressant & Sexual Dysfunction


- Sexual dysfunction, sleeping problems and weight gain are major reason for stopping anti-depressant treatment (60-75% of patients)
- 90% of patients stop prematurely with the medication
- Side effects early in treatment can decline, decrease or persist – but it will rarely disappear
- Sex is important for patients

# Treatment Of Medication Induced SD

- Wait for tolerance(10%)
- Dose-reduction
- Change of drug / Drug with less side effects
- "Drugholiday"
- Change sexual habits
- Pharmacological treatment of SD
  - PDE5-inhibitors
  - Antidote treatment
- Information/ couple therapy

# ANTIDOTES

- Bupropion (Zyban®) *dopamin & noradrenalin agonist*
- Bupiron (Buspar®) *5-HT<sub>1A</sub> partiel agonist*
- Mirtazapin (Remeron®) *adrenerg antagonist & 5HT<sub>3</sub> & 5HT<sub>2A</sub> antagonist*
  
- Sildenafil (Viagra®) *PDE5 inhibitor*
- Granisetron (Kytril®) *5HT<sub>3</sub> antagonist*
- Apomorfin SL *dopaminagonist*
- **Cyproheptadin** *serotonin antagonist*
- Yohimbin *adrenerg  $\alpha_2$  antagonist*
- Neostigmin *cholinerg agonist*
- **Amantadin** *dopamin agonist*
- **Dextroamfetamin** *dopamin agonist*

- 
- Emerging evidence that in some patients these SD side-effects persist after cessation of SSRI's >> **PSSD**
  - No-one know what withdrawal syndrome and **PSSD** actually are !!!
  - What is the treatment / How to manage ???

# PSSD

- Difficult to diagnose
- Difficult to treat
- Difficult to cure

Frustration for  
patient &  
physician

# What Is The Evidence

- Lareb database<sup>1</sup>:
  - 140,000 registrations, 44,000 about SSRI
  - 19 reports of PSSD
    - SSRI use: 9 days – 10 years
    - PSSD: 2 months – 2 years
  - 13 ♂ : 6 ♀
  - Mean age 30 years (20-59)
  - Paroxetine, Sertraline, Venlafaxine, Citalopram, Fluoxetine, Fluvoxine, Esitalopram
  - DE, Libido decrease, ED, Orgasmic disorders, reduced sensitivity
- Csoka<sup>2</sup>:
  - 3 males (20, 28 and 44 years old)
  - After use of SSIR's for different period (4-24 months)
  - Libido loss, ED, genital anesthesia

- Csoka & Shapro<sup>3</sup>:

- 2 ♂ & 1 ♀
- 24 – 30 years
- Libido loss, ED, numbness

- Bolton<sup>4</sup>:

- 26 years ♂
- Genital anesthesia, libido loss and orgasmic dysfunction
- 6 years after Sertraline

- Kaufman<sup>5</sup>

- 32 years ♀
- genital anesthesia and anorgasmia persist 1 year after Citalopram

- No relationship problems or Sexual complains prior to SSRI
- SD after start medication
- Depression in remission, no CVD risk factors
- Normal Serum T, LH, FSH, Cortisol, ACTH, Estrogen & Serotonin

➤ **Diminished Physical Capacity to Experience Sexual Pleasure**

<sup>1</sup> Dutch Pharmacovigilance database 2012

<sup>2</sup> CSoka AB, J Sex Med 2008

<sup>3</sup> Csoka AB Psychoth Psochosom 2006

<sup>4</sup> Bolton JM, J Sex Mart Therp 2006

<sup>5</sup> Kaufmann



# Possible Theories


- Serotonine increase in hypothalamus - down regulation receptors - Testosteron decrease
- Epigenetics: Serotonine transmission: single Nucleotide Polymorfism (SNP)
- Sodium chanals changes – decrease in Oxytocine release
- Transient Recptor Potentia Chanales (TLPR)
- Change in brain structures with SSRI (Amygadala,)
- Endocrine: SSRI & OAC more side effects, decreased Dopamine

# Contributing Factors

- Psychological
- Concomitant medical disorders
- Medications

# WHAT WE SHOULD DO?

- Registration and longer follow-up
- Informed consent before treatment
- When possible - avoid SSRI's
- Assess Sexual function before, during and after treatment
- When side effect:
  - Drug holiday
  - Reduce doses
  - Change to drug with less Sexual side effects (Bupropion, Mirtazapine, Nefazodone)\*

- 
- Multidisciplinary approach
    - Other contributing factors/ Psycho-pathology
  - History and Physical examination
  - Routine Laboratory and Hormones (TSH, LH, FSH, Testo, PRL, Estrogen)
  - Support & addressing the fear of permanent problem
  
  - Sleep, Nutrition, Physical activity, Routine
  - Avoiding of Alcohol & Drugs

# Anecdotal evidence

- Fenylethylamine (Wine, Chocolate, Chees) & Sofran
  - Reduction of symptoms severity
- Imipramine & Amineptine
  - increase dopamine transmission. Improvement of ejaculation
- Pramipexol (Dopamine agonist)
- Methylphenidole (Ritalin) –
  - Increase dopamine transmission
- Trazodone (5HT2 antagonist)
  - Reduction of SD severity
- Low-power laser irradiation for genital anesthesia

Thank you

Uro.Amsterdam@gmail.com



SAVE THE  
**DATE!**



ONE DAY PRE CONGRESS  
**UPDATE 2017**  
IN SEXUAL MEDICINE

**FROM KNOWLEDGE  
TO BEDSIDE PRACTICE**

1 February 2017 | Nice Acropolis | Nice, France

►► [www.essm-update2017.org](http://www.essm-update2017.org)

EUROPEAN SOCIETY  
FOR SEXUAL MEDICINE



19<sup>th</sup> CONGRESS OF THE EUROPEAN SOCIETY FOR SEXUAL MEDICINE  
2 – 4 February 2017 | Nice, France



Hosted by: AIUS (Association Interdisciplinaire post-Universitaire de Sexologie)  
and SFMS (Société Francophone de Médecine Sexuelle)

[www.essm.org](http://www.essm.org)